Histogenics Corporation (HSGX), a regenerative medicine company, focuses on developing and commercializing products in the musculoskeletal segment of the marketplace.
HSGX offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
HSGX has an exclusive channel collaboration agreement with Intrexon Corporation (XON) for the development and commercialization of allogeneic genetically modified chondrocyte cell therapeutics for the treatment or repair of damaged articular hyaline cartilage in humans.
Histogenics Corporation was founded in 2000 and is headquartered in Waltham, Massachusetts.
March 15, 2017
RegMed Investors’ (RMi) closing bell analysis: a goldilocks week, so far …
March 10, 2017
Regenerative Medicine Earnings Scorecard - Q4/2016 - to date
March 9, 2017
Histogenics (HSGX) publication of peer reviewed in the Journal of Orthopaedic Research
March 3, 2017
RegMed Investors’ (RMi) closing bell analysis, following the sector day by day
February 10, 2017
RegMed Investors’ (RMi) closing bell analysis, some sniffed the ugly as many bargains were recognized
February 9, 2017
RegMed Investors’ (RMi) closing bell analysis, today’s upside is a response to the sector’s last three out of four negative closes
February 9, 2017
RegMed Investors’ (RMi) mid-day analysis, momentum has a short fuse
February 8, 2017
RegMed Investors’ (RMi) closing bell analysis, mauled in the sector’s brawl
February 7, 2017
RegMed Investors’ (RMi) closing bell analysis, value perceived is not value achieved
February 7, 2017
Higher open expected; RegMed Investors’ (RMi) pre-open indications, distraught investors
35 companies, 1 interpreter!
Insight, foresight and recommendation
Histogenics (HSGX) -- Opened 2018 at $2.07, saw some ups at $2.92; opened February at $2.79 falling with a low of $2.50 to close 2/18 at $2.63.HSGX closed (1/25) its registered direct offering of 2,691,494 shares of its common stock, which includes 351,064 shares sold in connection with the exercise in full by the underwriter of its option to purchase additional shares. The total net proceeds of the offering are approximately $5.9 million after deducting the underwriting discounts and commissions with a solid book-running manager Canaccord Genuity. Another favorite ...
buyMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.